Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations

Documenti analoghi

• Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
  di: Song X, et al.
  Pubblicazione: (2017-06-01)
• Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
  di: Peng, Liang, et al.
  Pubblicazione: (2014)
• Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
  di: Kim, Eun Young, et al.
  Pubblicazione: (2018)
• EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
  di: Yang, Jiyoul, et al.
  Pubblicazione: (2018)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  di: Chen, Zhi-Yong, et al.
  Pubblicazione: (2012)